Epidemiology of vitamin D in health and disease

Sihe Wang

Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH, USA

Results from ecological, case–control and cohort studies have shown that vitamin D reduces the risk of bone fracture, falls, autoimmune diseases, type 2 diabetes, CVD and cancer. However, there is still epidemic vitamin D insufficiency especially among individuals living at high latitudes or with dark skin. Serum levels of 25-hydroxyvitamin D (25(OH)D) are considered the best biomarker of vitamin D nutritional status. Appropriate sunshine exposure or oral supplementation is necessary to maintain sufficient vitamin D status, which is generally accepted as serum 25(OH)D > 75 nmol/l. Immunoassays, especially RIA, have been primarily used to measure serum 25(OH)D while liquid chromatography–MS (LC–MS) is considered the ‘gold standard’. There is significant disparity among the immunoassays, and all immunoassays have considerable bias compared with LC–MS methods. Because of the variations among the results from these different assays, it is necessary that assay-specific reference ranges be established or standardisation of the assays take place. The present review focuses on ecological, case–control, and cohort studies that investigated the role of vitamin D in health and disease. In addition, analytical techniques used in laboratory evaluation of vitamin D nutritional status are also critically reviewed. The majority of the literature included in the present review is selected from that searchable in PubMed up to the end of September 2008.

Vitamin D: 25-Hydroxyvitamin D: Cancer: CVD: Autoimmune disease

Introduction

Even though the importance of vitamin D is gaining more public attention, rickets still exists in the USA in dark-skinned infants who are exclusively fed on breast milk(1). Rickets was first described in the literature in the mid-1600s, and cod-liver oil and sunshine exposure were recognised as the cures for rickets in the late 19th century. Vitamin D was then discovered in the early 20th century(1). There are two types of physiologically important vitamin D: cholecalciferol (D3) and ergocalciferol (D2). D3 is synthesised in the skin from 7-dehydrocholesterol in cell membranes upon exposure to UVB (290–320 nm), while D2 is plant and yeast derived and produced exogenously by UV irradiation of ergosterol(2,3). Vitamin D in the circulation is metabolised to 25-hydroxyvitamin D (25(OH)D) in the liver and further metabolised to the active metabolite, 1,25-dihydroxyvitamin D (1,25(OH)2D), in the kidney. The concentration of 1,25(OH)2D is highly regulated by a variety of factors including serum parathyroid hormone and P(2,4).

The majority of circulating 25(OH)D and 1,25(OH)2D is bound to vitamin D binding protein (DBP) (80–90%) and albumin (10–20%), while a small fraction of both 25(OH)D (0.02–0.05%) and 1,25(OH)2D (0.2–0.6%) is free(5). The vitamin D–DBP complex has been shown to be taken up by proximal tubules through the endocytic receptor megalin, after which DBP is proteolytically degraded, leaving the vitamin D metabolites for physiological action or metabolism(5,6). Thus, measuring free vitamin D metabolites is not clinically indicated despite some efforts having been made to calculate the free plasma vitamin D metabolites based on measured total concentrations, DBP, and albumin concentrations(7). The half-lives of vitamin D, 25(OH)D and 1,25(OH)2D are approximately 24 h, 3 weeks and 4 h respectively(5). In addition, liver production of 25(OH)D is not significantly regulated and is primarily dependent on the availability of vitamin D(5). Therefore measuring the total levels of serum 25(OH)D is considered the best estimate of vitamin D nutritional status.

Vitamin D nutritional status has been linked to many pathophysiological conditions. The present review will focus on ecological, case–control and cohort studies exploring the role of vitamin D in health and disease. Serum levels of 25(OH)D and the means of obtaining vitamin D will also be discussed. In addition, analytical

Abbreviations: DBP, vitamin D binding protein; LC–MS, liquid chromatography–MS; 25(OH)D, 25-hydroxyvitamin D; 1,25(OH)2D, 1,25-dihydroxyvitamin D; RR, relative risk.

Corresponding author: Dr Sihe Wang, fax +1 216 444 4414, email wangs2@ccf.org
techniques used in laboratory evaluation of vitamin D nutritional status will be critically reviewed.

Measuring vitamin D metabolites

There are a few commercial immunoassays available for measuring serum 25(OH)D, and liquid chromatography–MS (LC–MS) is considered the ‘gold standard’ \(^{(5)}\). However, reporting both 25(OH)D\(_2\) and 25(OH)D\(_3\) may be confusing to clinicians without appropriate guidance \(^{(8)}\). Both 25(OH)D and 1,25(OH)\(_2\)D\(_2\) were found to be stable at room temperature for at least 72 h in either whole blood or serum \(^{(9)}\). Exposure to UV light or freeze–thaw cycles (up to room temperature for at least 72 h in either whole blood or serum) \(^{(9)}\) can affect the stability of 25(OH)D. The stability of serum 25(OH)D was confirmed by DiaSorin RIA for up to four freeze–thaw cycles \(^{(10)}\).

The international Vitamin D Quality Assessment Scheme demonstrated that most commercial 25(OH)D methods were capable of producing reliable results for those samples containing only 25(OH)D\(_3\). However, the results were operator-dependent and most methods had significant bias compared with HPLC methods for samples with a substantial proportion of 25(OH)D\(_2\) \(^{(11)}\). Evaluation of current RIA and chemiluminescent methods for serum 25(OH)D using patient samples showed substantial variability among the six methods (RIA including DiaSorin assays and chemiluminescent immunoassays) and the same methods used in the different laboratories, which may confound the diagnosis of hypovitaminosis D \(^{(12)}\). Comparing to an HPLC method for serum 25(OH)D measurement, significant positive proportional bias was observed for DiaSorin and IDS RIA as well as the discontinued Nichols Advantage protein-binding assay in the range of 20–50 nmol/l in serum samples before D\(_2\) treatment \(^{(13)}\). All the immunoassays evaluated also underestimated serum 25(OH)D\(_2\) concentrations in samples after D\(_2\) treatment \(^{(13)}\). Using LC–MS as the standard, DiaSorin Liaison showed different but not clinically significant results (however, there were only eight patient samples treated with vitamin D\(_2\) included in the analysis) while the discontinued Nichols Advantage method showed significant difference \(^{(13)}\). A comprehensive evaluation of seven methods using 291 EDTA plasma samples (277 had no detectable 25(OH)D\(_2\) and fourteen had 25(OH)D\(_2\) between 5 and 8 nmol/l) showed that all methods except HPLC demonstrated considerable negative bias compared with LC–MS \(^{(15)}\). The deviation was more significant at levels of 25(OH)D > 75 nmol/l than those < 75 nmol/l for most immunoassays. The methods evaluated were HPLC, IDS RIA, IDS enzyme immunoassay (competitive immunoassay), Advantage (protein-binding assay), Liaison 1 and 2 (competitive immunoassay) and Elecsys (competitive electrochemiluminescent assay) \(^{(15)}\).

Most HPLC methods require lengthy sample preparation including solid-phase extraction \(^{(16)}\) and liquid–liquid extraction \(^{(17–19)}\), followed by a lengthy HPLC ranging from 10 to 30 min. It should be noted that potential late elution peaks may interfere with the analysis of the succeeding samples \(^{(16)}\). In addition, the C-3 epimer of 25(OH)D could be a significant interferant in infants < 1 year old, in which the epimer can be 8.7–61.1 % of the total 25(OH)D \(^{(16,20)}\).

The LC–MS is considered the ‘gold standard’ technology for 25(OH)D quantification \(^{(5)}\). Most LC–MS methods employ \(^{2}H_6\)-labelled 25(OH)D\(_3\) as the internal standard. \(^{2}H_6\)-labelled 25(OH)D\(_2\), while recently available, has a molecular weight of 418.2. With the loss of a water molecule, a fragment of 401.2 m/z is formed, interfering with 25(OH)D\(_3\) quantification. To improve ionisation efficiency, some methods employ a derivatisation strategy using a Cookson-type reagent \(^{(21,22)}\) or the Diels–Alder derivatisation \(^{(23)}\). For direct measurement without derivatisation, sample preparation can be cumbersome. In general, sample preparation includes protein precipitation followed by solid-phase extraction \(^{(24–26)}\) or liquid–liquid extraction \(^{(27–29)}\). Turbulent flow technology is a robust and rapid online purification tool for high efficiency extraction \(^{(30,31)}\) and has been used for online sample cleaning in serum 25(OH)D quantification \(^{(20)}\). This technology is efficient to reduce labour-intensive sample preparation and to improve reproducibility.

Serum levels of 25-hydroxyvitamin D

Vitamin D ‘deficiency’ refers to serum levels of 25(OH)D resulting in histologically evident bone diseases such as osteomalacia and rickets, while vitamin D ‘insufficiency’ refers to alterations in the parathyroid hormone concentration which if such persists over time may contribute to bone loss and fracture \(^{(2)}\). In general, rickets can occur for children with serum 25(OH)D less than 25 nmol/l (10 ng/ml) and osteoporosis is possible for adults with a serum 25(OH)D level at 80 nmol/l (32 ng/ml) or less \(^{(32,33)}\). Therefore, it is generally accepted that serum 25(OH)D levels of 25 and 75 nmol/l (30 ng/ml) are the cut-off values for deficiency and insufficiency, respectively \(^{(34,35)}\). Vitamin D insufficiency is recognised as an epidemic issue, especially in areas of higher latitudes or low sunlight and for individuals with darker skin \(^{(36)}\). It has been estimated that 40–90 % of the elderly worldwide have vitamin D insufficiency \(^{(34)}\). Even in southern parts of the USA, 45 % of black individuals and 11 % of white individuals aged 40–79 years had 25(OH)D ≤ 37.5 nmol/l \(^{(36)}\). In Canada, the majority (93 %) of children at ages 9, 13 and 16 years had insufficient vitamin D levels (≤ 75 nmol/l) and a significant fraction in each group had 25(OH)D ≤ 25 nmol/l, with higher percentages in the older groups \(^{(37)}\). The prevalence of vitamin D insufficiency (25(OH)D < 75 nmol/l) in adults with cystic fibrosis was 76 % in a retrospective study spanning 2 years at a cystic fibrosis centre in Atlanta (GA, USA) \(^{(38)}\). A 32 % higher risk for vitamin D insufficiency (25(OH)D < 75 nmol/l) was found for patients with chronic kidney disease in the Third National Health and Nutrition Examination Survey \(^{(39)}\).

Currently the most commonly agreed cut-off for vitamin D insufficiency is 25(OH)D < 75 nmol/l. This cut-off value was derived from studies using immunoassays or protein-binding assays which are significantly different from LC-based assays and vary significantly among these assays. Therefore, defining method-specific reference ranges or standardisation of 25(OH)D assays is important in
evaluation of vitamin D nutritional status and patient management.

**Effectiveness and safety of supplementation**

Both dietary supplementation and sunshine exposure are effective in preventing vitamin D deficiency, though there is concern of skin cancer due to prolonged solar UV radiation exposure\(^{(2,20)}\). There is clear evidence that UV light exposure, consuming vitamin D-fortified food and/or vitamin D supplementation has a positive impact on serum 25(OH)D. Individuals can tolerate vitamin D at doses above the current dietary reference intake levels which are 200 IU (1 μg = 40 IU) for children and adults up to 50 years of age, 400 IU for 51–70 years of age, and 600 IU for adults aged 71 years or older\(^{(3,41–43)}\). Short-term (8 weeks) and long-term (1 year) efficacy and safety for 14 000 IU/week supplementation of D3 were evaluated in children and no study subject developed vitamin D intoxication while mean serum 25(OH)D increased from 110 to 135 nmol/l and from 38 to 90 nmol/l, respectively\(^{(44)}\). At physiological inputs of both oral and cutaneous forms, there is a rapid conversion of vitamin D\(_2\) to 25(OH)D\(_2\); at low vitamin D\(_3\) concentrations and a much slower conversion rate at higher D\(_3\) concentrations\(^{(45)}\). Therefore, the increase of serum levels of 25(OH)D depends upon the serum vitamin D\(_3\) levels\(^{(45)}\). However, individual response to the same therapy (Calcichew D\(_3\) Forte containing 1250 mg calcium carbonate and 400 IU D\(_3\) per tablet\(^{(46)}\) was different; therefore, no single dose of vitamin D is appropriate for all\(^{(47)}\). In a 6-week randomised controlled study, supplementation with vitamin D\(_2\) 2000 IU daily, vitamin D\(_3\) 50 000 IU weekly, or vitamin D\(_3\) 2000 IU daily yielded equivalent outcomes (median increased from 42·5 to 90 nmol/l) in the treatment of hypovitaminosis D (25(OH)D < 50 nmol/l) among young children\(^{(48)}\). From a 6-month, prospective, randomised, double-blinded, double-dummy, placebo-controlled study of vitamin D\(_3\) supplementation, an optimal dose of 4600 IU daily is predicted to achieve serum 25(OH)D levels of 75–220 nmol/l\(^{(49)}\). In a different study involving 75–220 nmol/l are associated with a 26 % increased rate of all-cause mortality compared with the highest quartile (>80 nmol/l)\(^{(50)}\). The concentration range for reduced risk of mortality was 50–122·5 nmol/l, especially in women\(^{(57)}\). CVD and cancer mortalities were higher but not statistically significant in the lowest quartile of baseline 25(OH)D levels\(^{(57)}\). All-cause mortality but not CVD-cause mortality was higher in patients with 1,25(OH)\(_2\)D less than 52 pmol/l in 226 patients with chronic kidney disease stages 3 and 4\(^{(58)}\). Treatment with oral calcitriol was inversely associated with risk for mortality and combined death and dialysis initiation in predialysis patients with chronic kidney disease for a median duration of 2·1 years of 258 subjects receiving calcitriol and 262 subjects without calcitriol\(^{(59)}\). Though the study limitations included non-randomisation, observational design, lack of information on cause of death, the exclusive enrolment of men, and the small sample size, it emphasised the importance of vitamin D in the healthcare of this patient population and the immediate need for randomised prospective clinical trials\(^{(60)}\).

**Vitamin D and bones**

Vitamin D status plays a very important role in bone health. Rickets may present in children with serum levels of 25(OH)D < 25 nmol/l and osteoporosis is possible in adults with serum 25(OH)D levels < 80 nmol/l\(^{(52)}\). From a meta-analysis of double-blind randomised controlled trials of oral vitamin D supplementation (all used vitamin D\(_3\)) in older individuals (≥60 years) for either hip fracture (n 9294 subjects in five trials) or non-vertebral fracture (9820 subjects in seven trials), a vitamin D dose of 700–800 IU/d reduced risk of hip fracture by 26 % and non-vertebral fracture by 23 %, while no significant benefit was observed for 400 IU/d\(^{(61)}\). In a randomised double-blind controlled trial involving 2686 individuals, supplementation of 100 000 IU vitamin D\(_3\) once every 4 months resulted in significantly reduced fractures and mortality compared with the matching placebo-treated group\(^{(62)}\). The average serum 25(OH)D concentration in the supplementation group was 74·3 nmol/l v. 53·4 nmol/l in the placebo group\(^{(62)}\). Serum 25(OH)D was positively associated with bone mineral density at the hip and spine in 414 older men (mean age 74 years) at a clinic visit\(^{(63)}\). However, a prospective study involving 60 689 women aged 40–74 years in central Sweden found no association between either baseline
dietary Ca or vitamin D and fracture risk with an average follow-up of 11·1 years(64). In a case–control observational study within the European Prospective Investigation into Cancer and Nutrition-Oxford cohort, baseline plasma 25(OH)D levels (mean 80·4–83·7 nmol/l across the control and case groups) were not associated with fracture risk in 730 incident fracture cases and 1445 matched controls in 5 years after blood sample collection(65). In a 1-year randomised, double-blind, placebo-controlled trial involving 320 elderly women (age 77·2 (SD 4·6) years) whose serum 25(OH)D levels were less than 60 nmol/l, supplementation with 1000 IU vitamin D$_2$ did not have additional benefits on bone structure, bone formation markers, or intestinal Ca absorption over an additional 1000 mg Ca per d, though the serum 25(OH)D was raised from 44·3 (SD 12·9) nmol/l to 59·8 (SD 13·8) nmol/l(66). In conclusion, it is important to have adequate vitamin D for bone health and the doses higher than the current recommendation of dietary vitamin D are needed.

**Vitamin D and muscles**

Serum vitamin D levels are related to muscle strength, size and non-specific musculoskeletal muscle pain(32). In a meta-analysis of five double-blind randomised controlled trials involving 1237 participants (mean age, 60 years), vitamin D supplementation reduced the corrected OR of falling by 22 % compared with those on Ca or placebo(67).

In a retrospective cross-sectional study of haemodialysis patients receiving active vitamin D analogues for control of secondary hyperparathyroidism (n 49) v. those who were not (n 30), patients in the vitamin D group had a larger thigh-muscle cross-sectional area and were stronger across strength measures after controlling for age and sex(68). A low 25(OH)D level was associated with a high prevalence of falls in the previous year of blood draws in Japanese elderly women in a cross-sectional community-based survey involving 2957 subjects (950 men and 2007 elderly women aged 65–92 years)(69). In a retrospective study of 110 community-dwelling women with hip fractures, 96 % had 25(OH)D < 80 nmol/l and 38 % had 25(OH)D < 22·5 nmol/l(70). Those with 25(OH)D ≤ 22·5 nmol/l had poorer lower extremity function and higher falling rates compared with those with 25(OH)D > 22·5 nmol/l(70). Interestingly, higher testosterone levels had a decreased OR of falling and the fall reduction was further enhanced by vitamin D and Ca supplementation in 199 men and 246 women aged 65 + years living at home and followed for 3 years(71).

**Vitamin D and autoimmune diseases**

1,25(OH)$_2$D$_3$ regulates the growth and differentiation of multiple cell types displaying immunoregulatory and anti-inflammatory properties(72). Cells involved in innate and adaptive immune responses including macrophages, dendritic cells, T and B cells can produce and respond to 1,25(OH)$_2$D$_3$, leading to an enhancement of innate immunity and multifaceted regulation of adaptive immunity(72). Plenty of published ecological, case–control and cohort studies show the importance of vitamin D in a variety of autoimmune diseases(72,73).

In a prospective, nested case–control study among more than 7 million US military personnel, the risk of multiple sclerosis significantly decreased (OR 0·59) with every 50 nmol/l increase of serum 25(OH)D(74). A large case–control study based on death certificates by the National Cancer Institute found that the OR was 0·24 for the combined effect of the highest levels of residential and occupational sunlight exposure for multiple sclerosis while the OR was 1·38 for skin cancer(75). Vitamin D was also suggested for treatment and prevention of multiple sclerosis(76).

Vitamin D is also important in reducing type 1 diabetes. In a birth-cohort study with 10 366 children born in 1966 in Finland, vitamin D supplementation was associated with an 88 % reduction in type 1 diabetes incidence in 30 years of life(77). From a large multicentre trial covering many different European settings, vitamin D supplementation in infancy showed a protective effect for type 1 diabetes onset before the age of 15 years(78). Recently, age-standardised incidence rates of type 1 diabetes in fifty-one world regions in 1990–4 were shown to be significantly inversely associated with UVB irradiance adjusted for cloud cover(79).

Some epidemiological evidence shows that vitamin D status is associated with systemic lupus erythematosus, rheumatoid arthritis and other autoimmune diseases(72,80,81). However, more prospective controlled clinical research is needed in these areas.

**Vitamin D and type 2 diabetes**

Vitamin D deficiency impairs insulin secretion of pancreatic β-cells and increases insulin resistance in target tissues, both of which play critical roles in type 2 diabetes development(82). In the Nurses’ Health Study, 83 779 women with no history of diabetes, CVD or cancer were followed for 20 years(83). Risk of type 2 diabetes was reduced by total Ca intake or supplemental vitamin D, while a combined daily dose of > 1200 mg Ca and > 800 IU vitamin D was associated with a 33 % risk reduction of type 2 diabetes compared with those with Ca < 600 mg and < 400 IU vitamin D(83). Baseline serum 25(OH)D levels were inversely associated with the risk of type 2 diabetes in the Min-Finland Health Survey of 4097 eligible participants followed for 17 years(84). The relative risk (RR) of the highest (mean 70·9 nmol/l) to the lowest (mean 22·4 nmol/l) serum 25(OH)D quartiles was 0·60(84). In a combined analysis of two nested case–control studies with 412 cases and 986 controls in the Finnish Mobile Clinic Health Examination Survey (19 518 men and women aged ≥ 20 years) and the Mini-Finland Health Survey (8000 individuals aged ≥ 30 years) followed for 22 and 17 years, respectively, the relative odds of the highest (mean 70·9 nmol/l) to the lowest (mean 22·4 nmol/l) serum 25(OH)D quartiles was 0·60(84).

In a combined analysis of two nested case–control studies with 412 cases and 986 controls in the Finnish Mobile Clinic Health Examination Survey (19 518 men and women aged ≥ 20 years) and the Mini-Finland Health Survey (8000 individuals aged ≥ 30 years) followed for 22 and 17 years, respectively, the relative odds of the highest (mean 75 nmol/l) relative to the lowest (mean 24 nmol/l) quartiles of baseline serum 25(OH)D was 0·28 for type 2 diabetes in men but not significant in women who had lower serum 25(OH)D (highest quartile mean about 63 nmol/l)(82).

**Vitamin D and cardiovascular diseases**

The mechanisms of the protective role of vitamin D in CVD are proposed to be inhibition of vascular smooth muscle...
proliferation, suppression of vascular calcification, down-regulation of pro-inflammatory cytokines, up-regulation of anti-inflammatory cytokines, and the action of vitamin D as a negative endocrine regulator of the renin–angiotensin system\(^{93}\).

Baseline dietary vitamin D intake was found to be inversely associated with the risk of hypertension in 28,886 US women aged ≥ 45 years followed for 10 years in the Women’s Health Study\(^{98}\). In two prospective cohort studies including 613 men from the Health Professionals Follow-up Study and 1198 women from the Nurses’ Health Study followed for 4–8 years, the RR of incident hypertension among men whose plasma 25(OH)D levels were < 37.5 nmol/l was 6.13 compared with those whose levels were ≥ 75 nmol/l, while in women the RR was 2.67\(^{87}\).

A prospective nested case–control study of 18,225 men in the Health Professionals Follow-up study followed for 10 years showed that men with 25(OH)D ≤ 37.5 nmol/l had a RR of 2.42 for myocardial infarction compared with those with 25(OH)D ≥ 75 nmol/l\(^{88}\). Among 4839 participants of the National Health and Nutrition Examination Survey 2001–2004, the prevalence ratio of peripheral arterial disease after multivariable adjustment was 1.35 for each 25 nmol/l lower baseline serum 25(OH)D\(^{89}\). In a prospective cohort study of 3288 consecutive patients (mean age 62 years) scheduled for coronary angiography followed for a median of 7.7 years, the multivariate-adjusted hazard ratios for patients in the lower two serum 25(OH)D quartiles were 2.08 and 1.53 for all-cause death and 2.22 and 1.82 for cardiovascular mortality, respectively, compared with the highest quartile\(^{90}\). Similar but less significant relationships were also found for serum 1,25(OH)\(_2\)D\(^{90}\).

CVD is the leading cause of death (> 70%) in dialysis patients and some form of vitamin D intake is recommended in those patients\(^{91}\). Vitamin D deficiency has been known to affect cardiac contractility, vascular tone, cardiac collagen content and tissue maturation, while treatment with vitamin D improves survival rates in the patients with end-stage renal disease\(^{92}\). In a prospective cohort study (follow for 61 (SD 23) months) comparing the risk of death between users (n 162) and non-users (n 80) of oral 1,25(OH)\(_2\)D\(_3\) in a cohort of end-stage renal disease undergoing haemodialysis, the vitamin D users showed a hazard ratio of 0.287 compared with non-users for death from CVD\(^{93}\). Baseline serum 25(OH)D was significantly associated with a reduction of fatal or non-fatal cardiovascular events in 230 peritoneal dialysis patients followed for 3 years or until death with every 1-unit increase in log-transformed serum 25(OH)D associated with a 44% reduction\(^{94}\). Low serum levels of 25(OH)D and 1,25(OH)\(_2\)D were independent risk factors for fatal strokes during a median follow-up of 7.75 years in the Ludwigshafen Risk and Cardiovascular Health study with 3316 patients who were referred to coronary angiography\(^{95}\).

However, highly elevated serum 25(OH)D levels (≥ 222.5 nmol/l) had an adjusted OR of 3.18 for IHD in a cross-sectional case–control study with 143 patients with either angiographic evidence of coronary artery disease or acute myocardial infarction and seventy controls\(^{96}\). In a randomised prospective study involving 36,282 postmenopausal women (aged 50–79 years) in the Women’s Health Initiative study, supplementation of 500 mg calcium carbonate with 200 IU vitamin D\(_3\) twice daily neither increased nor decreased coronary or cerebrovascular risk in 7 years of follow-up\(^{97}\), probably due to the inadequate intervention vitamin D dose or concurrent use of vitamin D and/or Ca in the controls\(^{98}\).

Overall, there is strong evidence that maintaining sufficient vitamin D nutritional status has a significantly favourable impact on cardiovascular and cerebrovascular diseases.

### Vitamin D and cancer

1,25(OH)\(_2\)D-mediated repression or activation of proto-oncogenes or tumour-suppression genes that are related to cell proliferation and differentiation has been observed in a variety of normal and tumour tissues, including the small and large intestines\(^{99}\). This genetic mechanism seems responsible for the anti-cancer properties observed for vitamin D.

From ecological, case–control and cohort studies, sunlight was shown to be inversely associated with mortality or incidence of prostate, breast, ovary and colon cancer\(^{100–102}\). Serum levels and dietary vitamin D are associated with reduced risks of colorectal cancer and, less certainly, prostate cancer\(^{101}\). Solar UVB radiation was found to be associated with reduced risks of breast, colon, ovary, prostate and non-lymphoma cancer while an inverse correlation between mortality rates and UVB radiation was found for bladder, oesophageal, kidney, lung, pancreatic, rectal, stomach and corpus uteri cancer in a ecological study covering the entire USA with only a few states excluded\(^{103}\).

In a large cohort consisted of 416,134 skin cancer and 3,776,501 non-skin cancer as the first cancer extracted from thirteen cancer registries, risk for all second solid primary cancers except skin and lip cancers after skin melanoma were significantly lower for the sunny countries\(^{104}\). This relationship is more pronounced after non-melanoma skin cancer as the first cancer\(^{104}\). From a prospective cohort study (Health Professionals Follow-Up Study) followed for up to 14 years, serum 25(OH)D levels were predicted for 47,800 men via a multiple linear regression model including variables of dietary and supplementation vitamin D, skin pigmentation, adiposity, geographic residency and leisure-time physical activity\(^{105}\). From multivariable models, an increase in predicted serum 25(OH)D of 25 nmol/l was associated with a 17% reduction in cancer incidence and a 29% reduction in total cancer mortality\(^{105}\). In another prospective cohort study involving 363 renal transplant recipients followed for at least 3 years, pre-transplant serum 25(OH)D\(_3\) levels were inversely associated with cancer incidence after the transplantation\(^{106}\).

### Colorectal cancer

There are many trials reporting an inverse relationship between vitamin D and colorectal or colon cancer. In 12,823 men and 14,922 women with diagnosis of colon cancer, the survival rate 18 months after diagnosis was dependent on the season of diagnosis, with higher calculated serum
25(OH)D₃ levels at diagnosis offering better survival rates⁴⁰⁷. In a large cohort study of 34 702 postmenopausal women followed for 9 years, both Ca and vitamin D intakes were inversely associated with rectal cancer risk, though the trend for vitamin D was not significant⁴⁰⁸. It is worth mentioning that Ca and vitamin D intakes had additive protective effects for rectal cancer risk in the population⁴⁰⁸.

In a population-based, case–control study of colorectal cancer in Wisconsin women (678 controls, 348 colon and 164 rectal cancers), high Ca intake was associated with reduced colon and rectal cancer risk²⁹⁹. Similar relationships were found with vitamin D intake but were less significant⁴⁰⁹. In a population-based case–control study of 352 colon and 217 rectal cancers with 512 controls, dietary vitamin D was inversely associated with colorectal cancer risk, while dietary Ca was not⁴¹⁰. One shortcoming of the study is that the supplementation of vitamin D and Ca was not ascertained⁴¹⁰. In a prospective study of 60 866 men and 66 883 women followed for up to 5 years, both Ca and vitamin D intakes were inversely associated with colorectal cancer risk⁴¹¹.

From a large population-based study with 48 115 US women followed for 22 years, both Ca and vitamin D intakes were weakly inversely associated with distal colorectal adenoma risk, while vitamin D intake was strongly associated with reduced risk of distal colon adenoma²⁹⁸. In a multicentre randomised clinical trial of 1905 participants designed for dietary effects on recurrence of colorectal adenoma, dietary and supplement data were collected in each of the 4 years⁴¹³. Total vitamin D intake was weakly inversely associated with adenoma recurrence, while Ca was not³⁴³. Ca supplementation was found to reduce colorectal adenoma recurrence only when the serum 25(OH)D was > 72·8 nmol/l (median level) and serum 25(OH)D levels were inversely associated with the risk only among the subjects having the Ca supplement in a multicentre, placebo-controlled randomised trial of Ca supplementation for the prevention of colorectal adenoma recurrence involving 803 patients³⁴⁴.

However, there are many trials reporting non-significant relationship between vitamin D and colorectal or colon cancer. Both vitamin D and Ca intakes were found inversely associated with colon cancer risk in a prospective study of 47 935 US male health professionals followed for 6 years, but the associations were not significant after adjusted for confounding variables³⁴⁵. From a multi-state cohort study of 1993 colon cancer cases and 2410 population-based controls in the USA, dietary Ca but not dietary vitamin D was inversely associated with colon cancer risk³⁴⁶. Similarly, from a population-based study involving 61 463 women in Sweden followed for an average of 11·3 years, dietary Ca, not vitamin D, was weakly associated with colorectal cancer risk³⁴⁷. Intakes of Ca and vitamin D were not associated with the risk of colorectal cancer in a large, prospective, female cohort from the US Women’s Health Study with 39 876 women aged > 45 years followed for an average of 10 years³⁴⁸. Ca, but not vitamin D intake, was inversely associated with the risk of both colorectal adenoma and cancer in another large prospective cohort study of 73 034 French women followed for up to 7 years³⁴⁹. Daily supplementation of Ca with vitamin D for 7 years had no effect on the incidence of colorectal cancer among postmenopausal women in a randomised, double-blind, placebo-controlled trial involving 36 282 postmenopausal women from forty Women’s Health Initiative centres³⁵⁰.

To understand the conflicting results from these studies, a few factors should be considered: (1) subjects’ baseline intake of Ca and vitamin D; (2) duration of the studies, considering the long latency (10–20 years) of colon cancer; (3) insufficient vitamin D intake in the intervention studies, considering that serum 25(OH)D > 80 nmol/l is considered sufficient and most dietary studies had intake of only 400–500 IU/d³²,³¹. There are many confounders associated with dietary vitamin D studies including in vivo vitamin D synthesis upon exposure to UVB. Therefore, measuring serum levels of 25(OH)D is a more accurate way of assessing vitamin D status in a clinical study exploring the association of vitamin D with diseases.

In a case–control study with 473 primary distal colorectal adenoma cases and 507 controls, plasma 25(OH)D showed a linear trend (not statistically significant) toward decreasing risk of the adenoma³¹². A nested case–control study within a Finnish clinical trial cohort involving 146 cases (ninety-one colon, fifty-five rectal cancer) and 290 controls showed that baseline serum 25(OH)D, not 1,25(OH)₂D, in cases was significantly lower by 11·6 % with an average of 3·5 years between sample collection and case diagnosis³¹³. Another case–control study involving 239 colorectal adenoma and 228 controls showed an inverse association between serum 25(OH)D and colorectal adenoma risk; the relationship was strengthened by Ca intake above the median³¹⁴. A subset (179 colorectal cancer cases and 356 controls) of the Health Professionals Follow-up Study was followed for 8 years, and higher plasma 25(OH)D levels were significantly associated with decreased risk of colon cancer³¹⁵. When pooled with the Nurses’ Health Study, higher plasma 25(OH)D levels were significantly inversely associated with both colorectal and colon cancers³¹⁶. A more recent case–control study in Japan involving 375 colorectal cancers with two controls for each case showed that the lowest quartile of plasma 25(OH)D was associated with an increased risk of rectal cancer in both men and women, though no significant correlation was observed between plasma 25(OH)D and colorectal cancer in the 11·5-year follow-up after blood collection³¹⁷. An analysis of eighteen prospective cohort or retrospective case–control studies showed that individuals with intake of ≥ 1000 IU/d or serum 25(OH)D ≥ 82·5 nmol/l had a 50 % lower incidence of colorectal cancer compared with reference values (100 IU/d or < 32·5 nmol/l)/³¹⁸. A meta-analysis of five nested case–control studies of serum 25(OH)D in association with colorectal cancer risk showed that a 50 % lower risk of colorectal cancer was associated with serum 25(OH)D ≥ 82·5 nmol/l compared with serum 25(OH)D ≤ 30 nmol/l³¹⁹.

Breast cancer

Breast cancer is the most commonly diagnosed cancer in US women³²⁰. The vitamin D receptor is present in breast tissue and 1,25(OH)₂D has anti-proliferative and pro-differentiation effects on breast cancer cells³²¹. Vitamin D
and Ca are metabolically interrelated and are suggested in playing a role in the development of breast cancer by some epidemiological studies\(^{129}\). In an analysis of the first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study, among a cohort of 5009 white women followed for an average of 17.3 years, several measures of sunlight exposure and dietary vitamin D intake were associated with a reduced risk of breast cancer\(^{131}\). The highest risk reduction was observed for women who lived in US regions of high solar radiation while no risk reduction was observed for the women who lived in regions of low solar radiation\(^{131}\). In a population-based case–control study in Germany involving 278 premenopausal cases and 666 age-matched controls, vitamin D intake was significantly inversely associated with breast cancer risk\(^{132}\). During 16 years of follow-up of 88,691 women in the Nurses’ Health Study, both dairy Ca (RR 0.69; > 800 \(\mu g/d\)) and total vitamin D intake (RR 0.72; > 500 \(\mu g/d\)) had inverse associations with breast cancer risk in premenopausal but not postmenopausal women\(^{133}\). From a large prospective cohort study of 34,321 postmenopausal women followed for 18 years in the Iowa Women’s Health Study, women with vitamin D intake > 800 \(\mu g/d\) had an adjusted risk for breast cancer of 0.89 (weak association) compared with those with vitamin D intake < 400 \(\mu g/d\)\(^{134}\). From a population-based case–control study in Canada involving 972 newly diagnosed invasive breast cancer and 1135 controls, reduced breast cancer risk was associated with increased sunlight exposure from age 10 to 19 years\(^{135}\). In addition, cod liver oil use and increased milk consumption were also associated with a reduced risk of breast cancer\(^{135}\). The associations were weaker for women aged 20–29 years and null for women aged 45–54 years\(^{135}\). The importance of adolescent exposure to vitamin D on breast cancer risk reduction in adulthood was not observed in either the Nurses’ Health Study or the Nurses’ Health Study II in which during high school was assessed by dietary questionnaire at adulthood\(^{136,137}\). However, dietary Ca but not vitamin D was found to be inversely associated with breast cancer risk in the Cancer Prevention Study II Nutrition Cohort of 68,567 postmenopausal women followed up to 9 years\(^{138}\). Though these studies are important at initial identification of a vitamin D and breast cancer relationship, dietary vitamin D intake cannot be considered a complete assessment of vitamin D nutritional status\(^{129}\).

Among 790 breast cancer survivors in the Health, Eating, Activity, and Lifestyle Study, forty-nine (6.2%) had serum 25(OH)D < 25 nmol/l and 548 (69.4%) had serum 25(OH)D between 25 and 80 nmol/l\(^{139}\). The overall mean serum 25(OH)D was 62 (SD 26) nmol/l, while African American survivors had 45.3 (SD 21.8) nmol/l and Hispanic survivors had 55.3 (SD 23) nmol/l\(^{139}\). In a case–control study followed for about 6 years nested within the Nurses’ Health Study involving 701 cases and 724 controls, cases had a significantly lower plasma 25(OH)D than controls, while mean 1,25(OH)\(_2\)D levels were similar in the two cohorts\(^{140}\). Serum 25(OH)D was significantly inversely associated with postmenopausal breast cancer risk in a population-based case–control study in Germany with 1394 cases and 1365 controls\(^{141}\). Compared with the lowest category (< 30 nmol/l serum 25(OH)D), OR in other categories for breast cancer were 0.57 (30–45 nmol/l), 0.49 (45–60 nmol/l), 0.43 (60–75 nmol/l) and 0.31 (≥ 75 nmol/l)\(^{141}\). In a short-term (mean 3.9 years between blood draw and cancer diagnosis) prospective cohort case–control study in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, neither serum 25(OH)D nor 1,25(OH)\(_2\)D was associated with breast cancer risk in the postmenopausal women\(^{142}\). This negative finding may be due to the very short period of follow-up.

In conclusion, epidemiological evidence of protective effects of vitamin D on breast cancer risk is strong, though some conflicting data have been reported.

### Lymphoma

Strong evidence from case–control studies exists for protection against non-Hodgkin lymphoma by sun exposure and vitamin D intake. In a case–control study involving 704 adults with non-Hodgkin lymphoma and 694 controls in Australia, sun exposure was inversely associated with the risk of non-Hodgkin lymphoma, especially in women and in childhood\(^{143}\). Sunbathing and sunburns at age 20 years, 5–10 years before the interview, and sun exposure during vacations abroad were inversely associated with the risks of non-Hodgkin lymphoma as well as Hodgkin lymphoma, though the association was weaker for Hodgkin lymphoma in a population-based case–control study with 3740 patients and 3187 controls in Denmark and Sweden\(^{144}\). UV radiation exposure but not dietary vitamin D was associated with a reduced risk of non-Hodgkin lymphoma in a case–control study with 551 cases and 462 controls in the USA\(^{145}\). UV radiation exposure was also found to reduce overall lymphoma risk in a population-based case–control study with 710 paired malignant lymphoma cases and controls in Germany\(^{146}\). Total sun exposure was found inversely related to the risk of non-Hodgkin lymphoma in a population-based case–control study in the USA with 387 cases and 535 controls\(^{147}\). In a pooled analysis including ten case–control studies covering 8243 cases and 9697 controls in the USA, Europe and Australia, the risk of non-Hodgkin lymphoma fell significantly with the composite measure of increasing recreational sun exposure (OR 0.76 for the highest category)\(^{148}\). In a hospital-based case–control study with 190 cases and 484 controls, the risk of non-Hodgkin lymphoma was reduced by the intake of vitamin D, PUFA and linoleic acid\(^{149}\).

### Prostate cancer

There are perplexing data on the relationship between vitamin D and prostate cancer risk\(^{152}\). Analysis of a cohort of 3414 white men, among whom 153 developed prostate cancer after up to 21 years of follow-up in the First National Health and Nutrition Examination Survey Epidemiologic Follow-up Study, residential sunlight exposure was associated with significant and substantial reductions in prostate cancer risk\(^{150}\). An inverse correlation between the UVB levels and prostate cancer incidence and mortality rates were observed for white men, while for black men only prostate cancer incidence was significantly inversely...
associated with UVB radiation in the continental USA\(^{(151)}\). However, both higher latitude and July UVB radiation were associated with a higher risk of prostate cancer mortality rates in the USA in the periods of 1970–94 and 1950–69, indicating that both high and low levels of vitamin D impose risk for prostate cancer mortality\(^{(152)}\).

Effects of dietary vitamin D on prostate cancer can be confounded by other ingredients in the food that can be either risk enhancers or reducers for prostate cancer\(^{(152)}\). In a population-based case–control study in Sweden with 526 cases and 536 controls, dietary vitamin D intake was not associated with prostate risk while Ca intake was positively associated with prostate cancer risk\(^{(153)}\). Dietary vitamin D intake was shown not to be associated with prostate cancer risk in another population-based, case–control study involving 605 incident cases and 592 controls in the USA\(^{(154)}\). Dietary vitamin D was not significantly associated with prostate cancer risk, while Ca intake was a positive risk in a prospective study of 3612 men followed for up to 10 years in the First National Health and Nutrition Examination Survey Epidemiologic Follow-up Study\(^{(155)}\).

Comparing 1294 men with incident prostate cancer with 1451 men admitted to hospital for acute non-neoplastic diseases in Italy, no material association of dietary Ca or vitamin D with prostate cancer risk was found\(^{(156)}\). No association of either dietary vitamin D or Ca intake with prostate cancer risk was found for 82 483 men followed for a mean of 8 years in the Multiethnic Cohort Study\(^{(157)}\). In a meta-analysis of 26 769 cases from forty-five observational studies, neither dietary vitamin D nor Ca demonstrated a significant association with prostate cancer risk\(^{(158)}\). Most of the study subjects had very low vitamin D intake and therefore the true effects of vitamin D on prostate cancer might not be determined by these data.

Using serum or plasma levels of vitamin D metabolites as indicators of vitamin D nutritional status, many case–control studies showed no significant relationship between vitamin D and prostate cancer. In a nested case–control study including 232 cases and 414 age-matched controls in the 14 916 participants of the Physicians’ Health Study followed for 10 years, no significant association between either 25(OH)D or 1,25(OH)\(_2\)D and prostate cancer risk was observed\(^{(159)}\). No significant association was found between prostate cancer risk and either 25(OH)D or 1,25(OH)\(_2\)D in a nested case–control study in a cohort of 3737 Japanese American men followed for over 23 years\(^{(160)}\). In a prospective case–control study involving 460 men who developed prostate cancer and an equal number of controls in the Health Professionals Follow-up study followed for up to 5 years, there was no inverse association between plasma 25(OH)D or 1,25(OH)\(_2\)D and incident prostate cancer risk\(^{(161)}\). No significant inverse correlation between 25(OH)D or 1,25(OH)\(_2\)D with prostate cancer risk was observed in a nested case–control study involving eighty-three cases and 166 controls within the Nutrition Prevention of Cancer trial followed for up to 19 years\(^{(162)}\). No statistically significant trend was observed for overall prostate cancer risk with increasing season-standardised serum 25(OH)D in a nested case–control study with 749 cases and 781 controls within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial followed for up to 10 years\(^{(163)}\). However, serum 25(OH)D levels greater than the lowest quintile were associated with an increased risk of aggressive disease\(^{(163)}\).

Contrarily, there are studies showing a significant relationship between serum or plasma vitamin D status and prostate cancer risk. In a nested case–control study involving 149 prostate cancer cases and four controls for each case based on a 13-year follow-up of about 19 000 middle-aged men within the Helsinki Heart Study, prostate cancer risk was inversely associated with baseline serum 25(OH)D, with an OR of 1·7 for serum 25(OH)D levels below the median compared with those above the median\(^{(164)}\). This relationship was more pronounced among the young men (age < 52 years), with an OR of 3·5\(^{(165)}\). In a longitudinal nested case–control study with 622 prostate cancer cases and 1451 controls on Nordic men using serum banks of about 200 000 samples followed for up to 24 years, both low (\(\leq 19\) nmol/l) and high (\(\geq 80\) nmol/l) serum 25(OH)D had association with higher prostate cancer risk\(^{(165)}\). The optimal concentration of serum 25(OH)D was 40–60 nmol/l\(^{(165)}\). Low serum 25(OH)D (\(\leq 40\) nmol/l) significantly strengthened the relationship between the risk of prostate cancer and factors related to the metabolic syndrome while serum 25(OH)D was not significantly associated with prostate cancer risk in a longitudinal nested case–control study with 132 prostate cancer cases and 456 controls within a cohort of 18 939 Finnish middle-aged men followed for about 16 years in the Helsinki Heart Study\(^{(166)}\).

In a prospective case–control study with 1066 men with incident prostate cancer and 1618 controls among 14 916 men followed for 18 years within the Physicians’ Health Study, men with serum levels of both 25(OH)D and 1,25(OH)\(_2\)D below the medians had a significantly increased risk of aggressive prostate cancer\(^{(167)}\). There was also significant interaction between circulating 25(OH)D and vitamin D receptor genotype for prostate cancer risk\(^{(167)}\).

Overall, the relationship between prostate cancer risk and vitamin D nutritional status is conflicting and not conclusive. Genetic polymorphisms seem to play an important role. Further long-term comprehensive studies evaluating the effects of both serum levels of 25(OH)D and genetic variations in vitamin D receptor on prostate cancer risk are needed.

**Ovarian cancers**

The evidence on the relationship between vitamin D and ovarian cancer is contradictory and no definitive conclusion can be drawn from the data currently available.

Residential exposure to sunlight was significantly inversely correlated with mortality of ovarian cancer from data collected from 1984 to 1995 in twenty-four US states\(^{(102)}\). In an analysis of UVB data for July 1992 and cancer mortality rates in the USA for 1970–94, solar UVB radiation was associated with a reduced risk of ovarian cancer\(^{(103)}\). Fatal ovarian cancer in the 100 largest US cities in 1979–88 was inversely associated with mean annual intensity of local sunlight\(^{(168)}\). UVB irradiance was also inversely associated with ovarian cancer risk based on age-adjusted incidence rates for 175 countries using the
<table>
<thead>
<tr>
<th>Reference</th>
<th>Study design</th>
<th>Duration (years)</th>
<th>Study population</th>
<th>Low 25(OH)D</th>
<th>High 25(OH)D</th>
<th>OR (high/low)</th>
<th>Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melamed et al. (2008)</td>
<td>Survey</td>
<td>Up to 12</td>
<td>Third National Health and Nutrition Examination Survey</td>
<td>&lt; 44.5</td>
<td>&gt; 80.3</td>
<td>0.79*</td>
<td>Overall mortality (for women 25(OH)D &lt; 50 and &gt; 125 posed significant risk)</td>
</tr>
<tr>
<td>Trivedi et al. (2003)</td>
<td>Randomised double-blind controlled trial: 100,000 IU D₃ or placebo</td>
<td>5</td>
<td>General community dwellers, 65–85 years of age</td>
<td>53.4 (SD 21.1)</td>
<td>74.3 (SD 20.7)</td>
<td>0.78*</td>
<td>Fractures</td>
</tr>
<tr>
<td>Roddam et al. (2007)</td>
<td>Nested case–control</td>
<td>5</td>
<td>European Retrospective Investigation into Cancer and Nutrition-Oxford cohort</td>
<td>&lt; 50</td>
<td>≥ 100</td>
<td>1.26 (men); 0.94 (women)</td>
<td>Fractures</td>
</tr>
<tr>
<td>Suzuki et al. (2008)</td>
<td>Cross-sectional</td>
<td>1</td>
<td>Japanese community dwellers, 62–92 years of age</td>
<td>&lt; 50</td>
<td>≥ 50</td>
<td>1.71 (men); 0.66* (women)</td>
<td>Falls</td>
</tr>
<tr>
<td>LeBoff et al. (2008)</td>
<td>Retrospective</td>
<td>1</td>
<td>Community-dwelling women with hip fractures</td>
<td>≤ 22.5</td>
<td>&gt; 22.5</td>
<td>0.58*</td>
<td>Falls</td>
</tr>
<tr>
<td>Mungar et al. (2006)</td>
<td>Nested case–control</td>
<td>&lt; 1–13</td>
<td>US military personnel</td>
<td>&lt; 63.3</td>
<td>&gt; 99.1</td>
<td>0.38*</td>
<td>Multiple sclerosis</td>
</tr>
<tr>
<td>Mattila et al. (2007)</td>
<td>Prospective cohort</td>
<td>17</td>
<td>Mini-Finland Health Survey</td>
<td>&lt; 30</td>
<td>≥ 55</td>
<td>0.60*</td>
<td>Type 2 diabetes</td>
</tr>
<tr>
<td>Knekt et al. (2008)</td>
<td>Two nested case–control</td>
<td>17–22</td>
<td>Finish Mole Mini-Finland</td>
<td>≤ 32</td>
<td>≥ 58</td>
<td>0.28* (men)</td>
<td>Type 2 diabetes</td>
</tr>
<tr>
<td>Forman et al. (2007)</td>
<td>Prospective cohort</td>
<td>4–8</td>
<td>Health Professionals Follow-up</td>
<td>&lt; 37.5</td>
<td>≥ 75</td>
<td>0.16* (men)</td>
<td>Hypertension</td>
</tr>
<tr>
<td>Giovannucci et al. (2008)</td>
<td>Nested case–control</td>
<td>10</td>
<td>Health Professionals Follow-up</td>
<td>≤ 37.5</td>
<td>≥ 75</td>
<td>0.41*</td>
<td>Myocardial infarction</td>
</tr>
<tr>
<td>Melamed et al. (2008)</td>
<td>Survey</td>
<td>NA</td>
<td>National Health and Nutrition Examination Survey 2001–2004</td>
<td>&lt; 44.5</td>
<td>≥ 73</td>
<td>0.56*</td>
<td>Peripheral arterial disease</td>
</tr>
<tr>
<td>Dobnig et al. (2008)</td>
<td>Prospective cohort</td>
<td>Median 7.7</td>
<td>Patients scheduled for coronary angiography</td>
<td>≤ 25.3</td>
<td>≥ 59</td>
<td>0.45*</td>
<td>Cardiovascular mortality</td>
</tr>
<tr>
<td>Raisjee et al. (2001)</td>
<td>Cross-sectional case–control</td>
<td>NA</td>
<td>IHD v. controls</td>
<td>&lt; 222.5</td>
<td>≥ 222.5</td>
<td>3.18*</td>
<td>Total cancer incidence</td>
</tr>
<tr>
<td>Giovannucci et al. (2006)</td>
<td>Prospective cohort</td>
<td>Up to 14</td>
<td>Health Professionals Follow-up</td>
<td>NA</td>
<td>Increase of 25-0</td>
<td>0.83*</td>
<td>Colorectal cancer</td>
</tr>
<tr>
<td>Ducloix et al. (2008)</td>
<td>Prospective cohort</td>
<td>5</td>
<td>Kidney transplant patients</td>
<td>&lt; 25</td>
<td>≥ 80</td>
<td>0.71*</td>
<td>Total cancer mortality</td>
</tr>
<tr>
<td>Levine et al. (2001)</td>
<td>Case–control</td>
<td>NA</td>
<td>Primary adenoma v. controls</td>
<td>≤ 38</td>
<td>≥ 85.8</td>
<td>0.27*</td>
<td>Colorectal adenoma</td>
</tr>
<tr>
<td>Tangrea et al. (1997)</td>
<td>Nested case–control</td>
<td>1–7</td>
<td>Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study</td>
<td>≤ 24.5</td>
<td>≥ 48.3</td>
<td>0.6</td>
<td>Large bowel cancer</td>
</tr>
<tr>
<td>Peters et al. (2001)</td>
<td>Case–control</td>
<td>NA</td>
<td>Colorectal adenoma v. controls</td>
<td>NA</td>
<td>Increase of 25-0</td>
<td>0.74*</td>
<td>Colon cancer</td>
</tr>
<tr>
<td>Wu et al. (2007)</td>
<td>Nested case–control</td>
<td>Up to 8</td>
<td>Health Professionals Follow-up</td>
<td>Median 48.3</td>
<td>≥ 80.3</td>
<td>0.46*</td>
<td>Colorectal cancer</td>
</tr>
<tr>
<td>Otani et al. (2007)</td>
<td>Nested case–control</td>
<td>11–5</td>
<td>Japan Public Health Center-based Prospective Study</td>
<td>≤ 57.3</td>
<td>≥ 80.3</td>
<td>0.075* (men)</td>
<td>Colorectal cancer</td>
</tr>
<tr>
<td>Gorham et al. (2005)</td>
<td>Meta-analysis</td>
<td>2–8</td>
<td>General healthy population</td>
<td>&lt; 46.8</td>
<td>≥ 67.5</td>
<td>0.33 (women)</td>
<td>Colorectal cancer</td>
</tr>
<tr>
<td>Gorham et al. (2007)</td>
<td>Meta-analysis</td>
<td>2–25</td>
<td>General healthy population</td>
<td>&lt; 32.5</td>
<td>≥ 82.5</td>
<td>0.50*</td>
<td>Colorectal cancer</td>
</tr>
<tr>
<td>Bertone-Johnson et al. (2005)</td>
<td>Nesting case–control</td>
<td>6–7</td>
<td>Nurses’ Health Study Cohort</td>
<td>≤ 30</td>
<td>≥ 82.5</td>
<td>0.50*</td>
<td>Breast cancer</td>
</tr>
<tr>
<td>Abbass et al. (2008)</td>
<td>Case–control</td>
<td>NA</td>
<td>Postmenopausal residents</td>
<td>≤ 30</td>
<td>≥ 75</td>
<td>0.31*</td>
<td>Breast cancer</td>
</tr>
<tr>
<td>Freedman et al. (2008)</td>
<td>Prospective nested case–control</td>
<td>Mean 3.9</td>
<td>Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial</td>
<td>≤ 45.8</td>
<td>≥ 84.3</td>
<td>1.04</td>
<td>Breast cancer</td>
</tr>
<tr>
<td>Gann et al. (1996)</td>
<td>Nested case–control</td>
<td>10</td>
<td>Physicians’ Health Study</td>
<td>≤ 53.3</td>
<td>≥ 93.4</td>
<td>0.92</td>
<td>Prostate cancer</td>
</tr>
<tr>
<td>Nomura et al. (1998)</td>
<td>Nested case–control</td>
<td>23</td>
<td>Japanese-Americans in Hawaii</td>
<td>≤ 85</td>
<td>≥ 120</td>
<td>0.8</td>
<td>Prostate cancer</td>
</tr>
<tr>
<td>Jacobs et al. (2004)</td>
<td>Nested case–control</td>
<td>19</td>
<td>Nutritional Prevention Cancer Trial</td>
<td>≤ 63.3</td>
<td>≥ 82</td>
<td>0.75</td>
<td>Prostate cancer</td>
</tr>
<tr>
<td>Ahn et al. (2008)</td>
<td>Case–control</td>
<td>10</td>
<td>Prostate, Lung, Colorectal, and Ovarian Cancer Trial</td>
<td>≤ 42.5</td>
<td>≥ 71.8</td>
<td>1.25</td>
<td>Prostate cancer</td>
</tr>
<tr>
<td>Ahonen et al. (2000)</td>
<td>Nested case–control</td>
<td>13</td>
<td>Helsinki Heart Study</td>
<td>≤ 40</td>
<td>&gt; 40</td>
<td>0.59*</td>
<td>Gleason sum ≥ 7 or stage III or IV prostate cancer</td>
</tr>
<tr>
<td>Tuohimaa et al. (2004)</td>
<td>Nested case–control</td>
<td>Up to 24</td>
<td>Nordic men</td>
<td>≤ 19</td>
<td>40–59</td>
<td>0.67*</td>
<td>Prostate cancer</td>
</tr>
</tbody>
</table>

Note: IP address: 10.1017/S0954422409990151

Downloaded from https://www.cambridge.org/core/terms.
International Agency for Research on Cancer GLOBOCAN database\(^{(169)}\). In a case–control study in Mexico City with eighty-four new cases of ovarian cancer and 629 controls, dietary vitamin D intake was significantly associated with reduced ovarian cancer risk\(^{(170)}\). However, other dietary studies yielded negative results. In a hospital-based case–control study with 1031 ovarian cancer patients and 2411 controls in Italy, dietary vitamin D was not significantly associated with epithelial ovarian cancer risk\(^{(171)}\). A case–control study in Hawaii and Los Angeles with 558 patients and 607 controls did not show a significantly inverse association between dietary vitamin D and the risk of ovarian cancer\(^{(172)}\). No significant relationship was found for dietary vitamin D and ovarian cancer risk in a prospective cohort study among 31 925 subjects followed for an average of 8.3 years\(^{(173)}\). No significant association between dietary vitamin D intake and ovarian cancer risk was found in a meta-analysis of twelve prospective cohort studies that consisted of 553 217 women, among whom 2132 had epithelial ovarian cancer\(^{(174)}\). In a nested case–control study with 224 cases and 603 controls within the Nurses’ Health Study, Nurses’ Health Study II, and Women’s Health Study, neither plasma 25(OH)D nor 1,25(OH)\(_2\)D was significantly associated with ovarian cancer risk\(^{(175)}\).

### Other cancers

There are limited reports on the relationship between vitamin D nutrition status and the risk of other types of cancer. More prospective studies are needed.

In the Health Professionals Follow-up Study with 47 800 men followed for 14 years, an increment of plasma 25(OH)D of 25 nmol/l was associated with significant reduction of the following cancers: pancreatic cancer (RR 0.49); oesophageal cancer (RR 0.37); colorectal cancer (RR 0.63)\(^{(105)}\). In an analysis of two prospective cohort studies of 46 771 men in the Health Professionals Follow-up Study followed for 14 years and 75 427 women in the Nurses’ Health Study followed for 16 years, higher vitamin D intake was associated with a lower risk of pancreatic cancer\(^{(176)}\). The association was stronger in men than in women\(^{(176)}\). Contrarily, higher serum 25(OH)D was associated with an increased risk for pancreatic cancer in a prospective nested case–control study with 200 cases and 400 controls within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention cohort of male Finnish smokers\(^{(177)}\). However, caution should be taken in interpreting the results due to the special study population who smoked and obtained vitamin D primarily from fish, which may contain ingredients that increase the risk for pancreatic cancer\(^{(178)}\). Higher dietary vitamin D intake was associated with an increased risk for laryngeal cancer in a hospital-based case–control study with 527 cases and 1297 controls\(^{(179)}\).

In a prospective case–control study with 979 cases and 1105 controls followed for 6 years in China, higher serum 25(OH)D was associated with a higher risk for oesophageal squamous cell carcinomas in men but not in women\(^{(180)}\). No association was found between serum 25(OH)D with either gastric cardia or non-cardia adenocarcinoma\(^{(180)}\). It is noticeable that the serum 25(OH)D...
level was low in the study population, with the 75th percentile at 48.7 nmol/l\(^{190}\). Among 100 multiple myeloma cases, 40% had serum 25(OH)D \(\leq 36\) nmol/l, 35% had serum 25(OH)D 36–75 nmol/l, and only 25% had \(\geq 75\) nmol/l\(^{181}\). Based on the age-adjusted incidence rates for 175 countries in a UN cancer database (GLOBOCAN), lower levels of UVB and higher intakes of energy from animal foods were independently associated with a higher risk for kidney cancer\(^{182}\). No significant relationship was found between endometrial cancer and dietary vitamin D in a pooled analysis of three case–control studies\(^{183}\). Intermittent sun exposure was significantly inversely associated with the risk of death in 260 melanoma patients within a population-based case–control study in Italy followed for up to 21 years\(^{184}\).

Conclusions

There is strong evidence that maintaining sufficient vitamin D nutritional status is beneficial to bone health, muscle strength, cardiovascular and cerebrovascular diseases, autoimmune disease, type 2 diabetes and many types of cancer. The best biomarker for vitamin D nutritional status is serum level of total 25(OH)D. The epidemiological studies are heterogeneous in respect of study design, study population and technologies used for 25(OH)D quantification. Based on the data summarised in Table 1, serum 25(OH)D level of at least 50 nmol/l seems required for beneficial impact on general health, bone metabolism, muscle strength, autoimmune disease, type 2 diabetes, CVD and various cancers. The optimal serum 25(OH)D concentration may be over 75 or 80 nmol/l. However, 25(OH)D levels higher than 125 nmol/l or 225·5 nmol/l may present adverse impacts on general mortality and IHD, respectively. The best serum 25(OH)D level for prostate cancer prevention might be 40–60 nmol/l. Prospective intervention studies are needed to define the optimal levels of vitamin D nutritional status for a variety of diseases.

The sufficient level of vitamin D nutritional status is currently considered to be serum 25(OH)D > 75 nmol/l, which is derived from the clinical studies using immuno-assays or protein-binding assays. These assays show significant disparities among themselves and significant bias compared with LC–MS, which is considered the ‘gold standard’. Therefore, to better serve patients and advance the understanding of the relationship between vitamin D nutritional status and health and disease, assay-specific reference ranges should be established, or all assays should be standardised to LC–MS with an appropriate reference range established.

Acknowledgements

The present research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. The author declared no potential conflicts of interest.

References


